Pearl River Capital, LLC Biomarin Pharmaceutical Inc Transaction History

Pearl River Capital, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 13, 2024	BUY	$74.43 - $92.22 $212,199 - $262,919	2,851 Added 73.52%	6,729 $553,000
Q1 2024 May 14, 2024	BUY	$83.81 - $99.0 $325,015 - $383,922	3,878 New	3,878 $338,000
Q2 2023 Aug 11, 2023	BUY	$86.68 - $100.3 $830,307 - $960,773	9,579 New	9,579 $830,000
Q4 2022 Feb 13, 2023	SELL	$80.93 - $108.63 $1.54 Million - $2.07 Million	-19,026 Reduced 75.13%	6,297 $651,000
Q3 2022 Nov 14, 2022	BUY	$82.16 - $96.94 $1 Million - $1.19 Million	12,228 Added 93.38%	25,323 $2.15 Million
Q2 2022 Aug 12, 2022	SELL	$71.48 - $86.85 $490,781 - $596,312	-6,866 Reduced 34.4%	13,095 $1.09 Million
Q1 2022 May 13, 2022	BUY	$74.28 - $92.69 $1.48 Million - $1.85 Million	19,961 New	19,961 $1.54 Million
Q2 2020 Aug 10, 2020	SELL	$79.55 - $124.22 $121,472 - $189,683	-1,527 Closed	0 $0
Q1 2020 May 06, 2020	BUY	$71.37 - $96.85 $108,981 - $147,889	1,527 New	1,527 $129,000
Q1 2019 May 02, 2019	SELL	$84.2 - $98.62 $8,420 - $9,862	-100 Closed	0 $0
Q4 2018 Feb 08, 2019	BUY	$80.14 - $106.07 $8,014 - $10,607	100 New	100 $9,000

637

177M

2.01M

1.28M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Pearl River Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Pearl River Capital, LLC with notifications on news.